All News
Filter News
Found 67 articles
-
ImmPACT Bio provided an optimistic update on a Phase I clinical study evaluating its CD19-CD20 bi-specific Chimeric Antigen Receptor T-cell (CAR-T) therapy.
-
ImmPACT Bio Closes $111 Million Series B Financing, Names New Board Chair and New President and CEO, and Updates on Phase 1 Clinical Study in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
1/20/2022
ImmPACT Bio USA, Inc., a clinical-stage company developing transformative logic-gate based chimeric antigen receptor T-cell therapies for treating cancer, announced it has closed $111 million in Series B financing, led by venBio Partners along with co-leads Foresite Capital and Decheng Capital.
-
Janux Therapeutics to Present Virtually at the H.C. Wainwright BioConnect Conference
1/5/2022
Janux Therapeutics, Inc. announced that Janux management will participate in a fireside chat at the virtual H.C. Wainwright BioConnect Conference being held January 10 to 13.
-
Global TROP2 Antibody Drug Conjugate Market Clinical Trials Insight
12/2/2021
Trophoblast cell surface antigen-2 (Trop-2) is a 35-kDa transmembrane glycoprotein and calcium signal transducer encoded by the TACSTD2 gene, and is structurally related to epithelial cell adhesion molecule (EpCAM).
-
Janux Therapeutics Reports Business Highlights and Third Quarter 2021 Financial Results
11/9/2021
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the quarter ended September 30, 2021.
-
Janux Therapeutics to Present Virtually at Upcoming Investor Conferences
11/8/2021
Janux Therapeutics, Inc. today announced that Janux management will participate in fireside chats at two upcoming virtual investor conferences: Cowen’s 5th Annual IO Next Summit
-
Janux Therapeutics Appoints Ron Barrett, Ph.D., and Alana McNulty to Board of Directors
9/9/2021
Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced the additions of Ronald W. Barrett, Ph.D., and Alana McNulty as members of the Company’s Board of Directors.
-
Janux Therapeutics to Present Virtually at the H.C. Wainwright 23rd Annual Global Investor Conference
9/7/2021
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced that Janux management will present at the virtual H.C. Wainwright 23rd Annual Global Investor Conference.
-
Janux Therapeutics Reports Second Quarter 2021 Financial Results
8/10/2021
Janux Therapeutics, Inc., a biopharmaceutical company developing novel T cell engager immunotherapies based on its TRACTr platform technology, reported financial results for the quarter ended June 30, 2021.
-
Janux Therapeutics Appoints Shahram Salek-Ardakani, Ph.D., Chief Scientific Officer
7/19/2021
Janux Therapeutics, Inc. today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer.
-
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
6/15/2021
Janux Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock.
-
Janux Therapeutics Announces Pricing of Initial Public Offering
6/11/2021
Janux Therapeutics, Inc., a biopharmaceutical company developing novel T cell engager immunotherapies, announced the pricing of its initial public offering of 11,400,000 shares of its common stock at a price to the public of $17.00 per share.
-
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
-
BioSpace Movers & Shakers, June 4
6/4/2021
Biopharma and life sciences organizations strengthen their leadership teams and board with these Movers & Shakers. -
Janux Therapeutics Appoints Dr. Wayne Godfrey as Chief Medical Officer
6/3/2021
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.
-
Money on the Move: May 19-25
5/26/2021
Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars. -
Janux plans to use the funds raised from the IPO to submit four Investigational New Drug applications to the U.S. FDA in the first half of 2022.
-
Money on the Move: April 14-20
4/21/2021
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week. -
Janux Therapeutics Closes $125 Million Series B Financing to Advance Next Generation T Cell Engager Immunotherapies into Clinical Trials
4/20/2021
Janux Therapeutics today announced the closing of a $125 million Series B financing led by RA Capital Management and joined by new investors BVF Partners L.P., EcoR1 Capital, Hartford HealthCare Endowment, Janus Henderson Investors, Logos Capital, Samsara BioCapital and Surveyor Capital (a Citadel company). Janux’s existing investors, OrbiMed, Avalon Ventures, and Bregua, also participated.
-
Janux Therapeutics Appoints Charles Winter Senior Vice President of Chemistry, Manufacturing, and Controls
3/30/2021
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Charles Winter as Senior Vice President of Chemistry, Manufacturing, and Controls (CMC)